Sarasota, Fla. – October 07, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) reported that its Bisphosphocin compound Nu-8, delivered intravesically to rodents infected with E. coli, achieved up to 97% inhibition of bacterial growth using a 10% solution, against no effect in a vehicle control group.
Nu-8 targets drug-resistant bacteria linked to catheter-associated UTIs
The Bisphosphocin class has shown in vitro activity against a broad range of resistant bacteria common in urinary tract infections, including E. coli, K. pneumoniae, and P. aeruginosa, and against biofilm-forming organisms. Complicated UTIs, particularly catheter-associated urinary tract infections, are frequently driven by drug-resistant strains and biofilm formation, a persistent challenge for hospital infection control.
Aerosol formulation shows activity in pulmonary infection models
Separately, aerosolized Bisphosphocin compounds demonstrated in vivo activity in animal models of pulmonary infections caused by Acinetobacter species, P. aeruginosa, and A. fumigatus. The class also showed in vitro activity against H. influenzae, K. pneumoniae, and P. aeruginosa — pathogens tied to community-acquired, hospital-acquired, and ventilator-acquired bronchial pneumonia, as well as recurrent infections in cystic fibrosis patients.
CEO cites no expected resistance development across compound class
"The Bisphosphocin class of compounds possesses key characteristics including rapid and potent antimicrobial action and broad-spectrum activity with no expected resistance development, which could make them valuable assets in fighting the AMR crisis," said Kelvin Cooper, Ph.D., CEO and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics.
Lead candidate Nu-3 advances in Phase 2a diabetic foot ulcer trial
The company's lead Bisphosphocin candidate, Nu-3, formulated as a topical gel, is in an ongoing Phase 2a trial for mildly infected diabetic foot ulcers, with topline data expected in the first quarter of 2027.